Evaluation of 111In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 2, 2003, Pages 249-252

  Bernhardt, Peter ^a   Ahlman, H ^a   Nilsson, O ^a   Benjegard S A ^a   Forssell Aronsson, E ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETIC ACID DEXTRO PHENYL OCTREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN IN 111; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

CELL DENSITY; CELL SURVIVAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DOSIMETRY; DRUG EFFECT; DRUG UPTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOACTIVITY;

CARCINOMA, SMALL CELL; CELL SURVIVAL; HUMANS; INDIUM RADIOISOTOPES; LUNG NEOPLASMS; OCTREOTIDE; PENTETIC ACID; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0038066691     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803765036427     Document Type: Conference Paper

References (13)

1. 1-octreotide. J Nucl Med 37(12):2002-2006, 1996.
2. McLean JR, Blakey DH, Douglas GR, Bayley J. The Auger electron dosimetry of indium-111 in mammalian cells in vitro. Radiat Res 1989;119:205-218.
3. 1-octreotide in patients with neuroendocrine tumors. J Nucl Med 2000; 41:1514-1518.
4. Progressive nuclear translocation of somatostatin analogs. Homick C, Anthony C, Hughey S, Gebhardt B, Espenan G, Woltering E. J Nucl Med 2000; 41:1256-1263.
5. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. Mariani G, Bodei L, Adelstein S.J, Kassis A.I. J Nucl Med 2000; 41:1519-1521.
6. Howell R.W, Rao D.V, Haydock C. Dosimetry techniques for therapeutic applications of incorporated radionuclides. In The joint symposium on dosimetry of administered radionuclides, Proceedings held at Washington D.C, September 1989: 215-256.
7. Berger M.J. Improved point kernels for electron and beta ray dosimetry. National Bureau of Standards, NBSIR 73-107, Washington, 1973.
8. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: Absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994;35:303-319.
9. Goddu M.S, Rao D.V, Howell R.W. Multicellular dosimetry for micrometastasis: dependence of selfdose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med 1994;35:521-530.
10. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skamemark G. Low-energy electron emitters for targeted therapy of small tumours. Acta Oncologica 2001;41:6+2-608.
11. 177Lu, is most promising for radionuclide therapy of somatostatin receptor-positive tumours. Nucl Med Comm 2000; 21(6): 569.
12. Brownell GL, Ellett WH, Reddy AR. Absorbed fractions for Photon dosimetry. J Nucl Med 1968;supplement 1:27-39.
13. Ellett W.H, Humes R.M. Absorbed fractions for small volumes containing photon-emitting radioactivity. MIRD Pamphlet No.8, J Nucl Med 1971; 12(suppl 5):25-32.